Sylvia Musto

1.8k citations

32 papers · 943 indexed · h-index 18

Impact in

Oncology top 10%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
Biotechnology top 10%
- Marine Sponges and Natural Products

Papers in

Oncology 15
- HER2/EGFR in Cancer Research 10
- Cancer Treatment and Pharmacology 4
Cell Biology 8
- Microtubule and mitosis dynamics 6

Co-authors: Frank Loganzo Xingzhi Tan Tami Annable Lee M. Greenberger Robert S. Schwartz Malathi Hari Anne C. Rybicki Ronald L. Nagel
Journals: Blood (5 papers)Cancer Research (4 papers)Bioorganic & Medicinal Chemistry Letters (3 papers)Bioconjugate Chemistry (3 papers)Molecular Cancer Therapeutics (2 papers)
Partner nations: United States Canada Germany

In The Last Decade

Sylvia Musto

31 papers receiving 909 citations

Peers

Countries citing papers authored by Sylvia Musto

Since Specialization

Citations

This map shows the geographic impact of Sylvia Musto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvia Musto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvia Musto more than expected).

Fields of papers citing papers by Sylvia Musto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvia Musto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvia Musto. The network helps show where Sylvia Musto may publish in the future.

Co-authors

The 25 scholars most cited alongside Sylvia Musto, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sylvia Musto Line = papers co-authored together Sylvia Musto links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Novel PIKK inhibitor antibody-drug conjugates: Synthesis and anti-tumor activity Bioorganic & Medicinal Chemistry Letters ·Dahui Zhou, Jeffrey Casavant, Edmund I. Graziani, Haiyin He, Jeffrey E. Janso, Frank Loganzo, Sylvia Musto, 英昭大利, Christopher J. O’Donnell, Russell G. Dushin	2019	10
2	Establishing in vitro–in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach Journal of Pharmacokinetics and Pharmacodynamics ·Dhaval K. Shah, Frank Loganzo, Nahor Haddish‐Berhane, Sylvia Musto, Javier Miranda Mallea, Frank Barletta, Judy Lucas, Tracey Clark, Débora Soares Carvalho, Alison Betts	2018	17
3	Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates The AAPS Journal ·L. Nathan Tumey, Fengping Li, Brian Rago, Xiaogang Han, Frank Loganzo, Sylvia Musto, Edmund I. Graziani, Sujiet Puthenveetil, Jeffrey Casavant, Kimberly Marquette, Tracey Clark, Jack Bikker, Eric M. Bennett, Frank Barletta, Nicole Piche‐Nicholas, Amy Tam, Christopher J. O’Donnell, Hans Peter Gerber, Lioudmila Tchistiakova	2017	48
4	Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate PLoS ONE ·Sujiet Puthenveetil, Haiyin He, Frank Loganzo, Sylvia Musto, Jesse A. Teske, Michael R. Green, Xingzhi Tan, Christine Hosselet, Judy Lucas, L. Nathan Tumey, Puja Sapra, Chakrapani Subramanyam, Christopher J. O’Donnell, Edmund I. Graziani	2017	20
5	Design, Synthesis, and Cytotoxic Evaluation of Novel Tubulysin Analogues as ADC Payloads ACS Medicinal Chemistry Letters ·Carolyn A. Leverett, Sai Chetan K. Sukuru, Beth C. Vetelino, Sylvia Musto, Kevin Parris, Jayvardhan Pandit, Frank Loganzo, Alison H. Varghese, Guoyun Bai, Bin Liu, Dingguo Liu, Sarah P. Hudson, Venkata Ramana Doppalapudi, Joseph R. Stock, Christopher J. O’Donnell, Chakrapani Subramanyam	2016	27
6	Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates Bioconjugate Chemistry ·Sujiet Puthenveetil, Sylvia Musto, Frank Loganzo, L. Nathan Tumey, Christopher J. O’Donnell, Edmund I. Graziani	2016	49
7	Synthesis, Molecular Editing, and Biological Assessment of the Potent Cytotoxin Leiodermatolide Journal of the American Chemical Society ·Damien Mailhol, Jens Willwacher, Nina Kausch‐Busies, Duus Jesper, Zhanna Sobol, Maik Schuler, My‐Hanh Lam, Sylvia Musto, Frank Loganzo, Andreas Maderna, Alois Fürstner	2014	84
8	New cytotoxic benzosuberene analogs. Synthesis, molecular modeling and biological evaluation Bioorganic & Medicinal Chemistry Letters ·Zecheng Chen, Andreas Maderna, Sai Chetan K. Sukuru, M. Wagenaar, Christopher J. O’Donnell, My‐Hanh Lam, Sylvia Musto, Frank Loganzo	2013	17
9	Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules Molecular Cancer Therapeutics ·Malathi Hari, Frank Loganzo, Tami Annable, Xingzhi Tan, Sylvia Musto, Sai Kiran K M, James H. Nettles, James P. Snyder, Lee M. Greenberger	2006	120
10	Hybrids of the Hemiasterlin Analogue Taltobulin and the Dolastatins Are Potent Antimicrotubule Agents Journal of the American Chemical Society ·Arie Zask, Joshua A. Kaplan, Sylvia Musto, Frank Loganzo	2005	22
11	Hemiasterlin analogs exclusively label α-tubulin at the interdimer region and specifically block subtilisin digestion of α-tubulin Cancer Research ·Malathi Hari, Maria Nunes, Arie Zask, Joshua A. Kaplan, Joseph L. Wooters, Albert A. Minnick, A A Vlasov, Sylvia Musto, Carl F. Beyer, Girija Krishnamurthy, Yongchang Qiu, Frank Loganzo, Semiramis Ayral‐Kaloustian, Lee M. Greenberger	2004	1
12	Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin. PubMed ·Frank Loganzo, Malathi Hari, Tami Annable, Xingzhi Tan, Sai Kiran K M, Sylvia Musto, Arie Zask, Joshua A. Kaplan, Albert A. Minnick, A A Vlasov, Semiramis Ayral‐Kaloustian, Marianne S. Poruchynsky, Tito Fojo, Lee M. Greenberger	2004	25
13	Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment Bioorganic & Medicinal Chemistry Letters ·Ayako Yamashita, S.V. Trofimovich, Joshua A. Kaplan, Forum for African Women Educationalists, Frank Loganzo, Richard Hernandez, Carl F. Beyer, Tami Annable, Sylvia Musto, Carolyn Discafani, Arie Zask, Semiramis Ayral‐Kaloustian	2004	16
14	Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in α-tubulin Molecular Cancer Therapeutics ·Frank Loganzo, Malathi Hari, Tami Annable, Xingzhi Tan, Sai Kiran K M, Sylvia Musto, Arie Zask, Joshua A. Kaplan, Albert A. Minnick, A A Vlasov, Semiramis Ayral‐Kaloustian, Marianne S. Poruchynsky, Tito Fojo, Lee M. Greenberger	2004	24
15	Molecular Identification and Expression of Erythroid K:Cl Cotransporter in Human and Mouse Erythroleukemic Cells Blood Cells Molecules and Diseases ·Christine Pellegrino, Anne C. Rybicki, Sylvia Musto, Ronald L. Nagel, Robert S. Schwartz	1998	61
16	Two Distinct Pathways Mediate the Formation of Intermediate Density Cells and Hyperdense Cells From Normal Density Sickle Red Blood Cells Blood ·Robert S. Schwartz, Sylvia Musto, Mary E. Fabry, Ronald L. Nagel	1998	24
17	Two Distinct Pathways Mediate the Formation of Intermediate Density Cells and Hyperdense Cells From Normal Density Sickle Red Blood Cells Blood ·Robert S. Schwartz, Sylvia Musto, Mary E. Fabry, Ronald L. Nagel	1998	3
18	Decreased content of protein 4.2 in ankyrin-deficient normoblastosis (nb/nb) mouse red blood cells: evidence for ankyrin enhancement of protein 4.2 membrane binding Blood ·John F. Bender, Sylvia Musto, RS Schwartz	1995	10
19	Human erythrocyte protein 4.2 deficiency associated with hemolytic anemia and a homozygous 40glutamic acid-->lysine substitution in the cytoplasmic domain of band 3 (band 3Montefiore) Blood ·John F. Bender, E. Nokay, Sylvia Musto, Katia Capuccini, RL Nagel, RS Schwartz	1993	70
20	Human erythrocyte protein 4.2 deficiency associated with hemolytic anemia and a homozygous 40glutamic acid-->lysine substitution in the cytoplasmic domain of band 3 (band 3Montefiore) Blood ·John F. Bender, E. Nokay, Sylvia Musto, Katia Capuccini, RL Nagel, RS Schwartz	1993	3

About Sylvia Musto

Sylvia Musto is a scholar working on Oncology, Cell Biology, Radiology, Nuclear Medicine and Imaging, Genetics and Toxicology, having authored 32 papers that have together received 943 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (10 papers), Monoclonal and Polyclonal Antibodies Research (10 papers), Erythrocyte Function and Pathophysiology (7 papers), Microtubule and mitosis dynamics (6 papers), Ubiquitin and proteasome pathways (6 papers), Glycosylation and Glycoproteins Research (4 papers), Neonatal Health and Biochemistry (4 papers) and Cancer Treatment and Pharmacology (4 papers). The work is most often cited by research in Oncology (328 citations), Biotechnology (88 citations), Cell Biology (160 citations), Organic Chemistry (216 citations) and Radiology, Nuclear Medicine and Imaging (165 citations). Sylvia Musto has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Frank Loganzo, Xingzhi Tan, Tami Annable, Lee M. Greenberger, Robert S. Schwartz, Malathi Hari, Anne C. Rybicki, Ronald L. Nagel, Christopher J. O’Donnell and Arie Zask. Their work appears in journals such as Blood, Cancer Research, Bioorganic & Medicinal Chemistry Letters, Bioconjugate Chemistry and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact